Non‐serious adverse events · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
1 finding from 1 review
Non‐serious adverse events · adults with oesophageal varices
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events (secondary outcome) · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether non‐absorbable disaccharides changes non‐serious adverse events (secondary outcome) compared with placebo/no intervention (very low certainty).
1 finding from 1 review
Non‐serious adverse events · farmworkers, soldiers, and people in endemic areas
It is very uncertain whether summary of findings table ‐ Antibiotics changes non‐serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Non‐serious adverse events · people with chronic liver diseases
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Non‐serious adverse events · patients with primary biliary cirrhosis.
It is very uncertain whether ursodeoxycholic acid changes non‐serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious · people with leptospirosis
It is very uncertain whether summary of findings table ‐ Antibiotics changes adverse events considered non‐serious compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Non‐serious adverse events assessed using ICH‐GCP
It is very uncertain whether L‐ornithine L aspartate changes non‐serious adverse events assessed using ICH‐GCP compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Non‐serious adverse events ‐ total number of particiapnts · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of particiapnts compared with placebo/no intervention (very low certainty).
1 finding from 1 review
Non‐serious adverse events (range 2–10 months) · adult patients after liver transplantation.
1 finding from 1 review
Non‐serious adverse events (secondary outcome) · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether lactulose changes non‐serious adverse events (secondary outcome) compared with lactitol (very low certainty).
1 finding from 1 review